Treatment 'breakthrough' in man with advanced skin cancer
Conclusion This is described as the first case study in humans to have successfully combined these immune treatments. The results demonstrate that long-term cancer remission was achieved even after the cancer had previously progressed quickly when the person had been given IL-21, CTL and anti-CTLA4 separately. These seem to be extremely encouraging findings for metastatic melanoma, a cancer with notoriously poor prognosis. However, before the findings raise too much hope, it must be emphasised that this case report focuses on just one man. The researchers note he is one of 10 people entered into the trial of this combination treatment, and only one other person received complete remission as well. This means this treatment combination may not offer the hope of a complete cure for all people who have reached the advanced stages of this aggressive cancer. It is unclear why these two people responded so positively to treatment, while the other eight did not. However, new treatment possibilities for advanced melanoma are always welcome. It is hoped that researchers may be able to build on these encouraging results in future trials to find out which people with metastatic melanoma are likely to be suited to this treatment and would benefit the most from it – for example, by looking at characteristics of their cancer, cell profile and previous treatment. For now, the most important message for malignant melanoma remains that prevention is better tha...
Org. Biomol. Chem., 2018, Accepted Manuscript DOI: 10.1039/C8OB01526K, PaperQianqian Wang, Xiaoli An, Jiahui Xu, Yuwei Wang, Liang Liu, Lai-Han Leung, Xiaojun Yao Selective modulation of individual bromodomains (BDs) by small molecules represents an important strategy for the treatment of various cancers, considering that the BD-containing proteins share common BD structures and distinct... The content of this RSS Feed (c) The Royal Society of Chemistry
Dalton Trans., 2018, Accepted Manuscript DOI: 10.1039/C8DT01724G, PaperSrinivasareddy Telukutla, Steven Priv ér, Vijay Venoba Rao, Nedaossadat Mirzadeh, Suresh K. Bhargava A series of gold(I), gold(III) and cationic gold(I) complexes of tris(4-methoxyphenyl)phosphine and tris(2,6-dimethoxyphenyl)phosphine were synthesized and fully characterized by spectroscopic methods. The molecular structures of selected complexes were also determined... The content of this RSS Feed (c) The Royal Society of Chemistry
The idea that lifestyle changes have made the disease more common is a gross exaggeration – but increasingly prevalent. We separate fact from fictionCancer is not up there withthe most likely explanations for what caused the mass extinction 66m years ago of the T rex and the triceratops. That said, at leastone species of dinosaur suffered from blood-vessel tumours – anda 1.7m-year-old toe with bone cancer was discovered in 2016 at a South African world heritage site.Cancer may have been more common in ancient times than we will ever know, because fossilisation will have obliterated most evidence of the disease....
While football (soccer) training may be a potent strategy for health promotion in older men, the considerable risk of injuries may constitute a barrier for referral of clinical populations. The current study explored the attitudes of men with prostate canc...
LUNG cancer symptoms usually begin to show as the condition progresses, with no indications in the early stages. But when they do become apparent the most common sign is a cough, particularly one that won ’t go away or gets worse. There are seven symptoms of the disease all together to look out for.
[Premium Times] A Professor of Pharmacognosy at Obafemi Awolowo University, Joseph Aladesanmi, who invented a yet to be clinically tested anti-cancer drug, has decried poor funding of research in Nigeria.
Chinese regulators are speeding up drug approvals, with Roche's Alecensa cancer medicine the latest beneficiary in a market that is growing increasingly important for international pharmaceuticals companies' growth plans.
Michelle A. Kelliher, Justine E. Roderick
Roche today announced that the China National Drug Administration (CNDA) has granted marketing authorisation for Alecensa ® (alectinib) as a monotherapy treatment for patients with anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer (NSCLC).
(Elsevier) A report in The Journal of Molecular Diagnostics describes a new assay, anchored multiplex PCR (AMP)-based targeted next-generation-sequencing (NGS), with superior diagnostic utility compared to conventional techniques. This includes the ability to analyze numerous target genes simultaneously and identify new fusion partners. In four cases, the assay diagnosed sarcoma in samples deemed falsely negative by conventional tests.
More News: Allergy & Immunology | Biotechnology | Brain | Brain Cancers | Cancer | Cancer & Oncology | Chemotherapy | Eyes | Graduation | Grants | Health | Immunotherapy | Lung Transplant | Melanoma | Men | Neurology | Science | Skin | Skin Cancer | Study | University of Washington | Vitiligo | Yervoy